Amgen Inc (AMGN)

227.57 +0.70 (+0.31%)
Real-time Cboe USD Disclaimer

Amgen Inc Company Profile

Equity Type
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.
Contact Information
Thousand Oaks,91320-1799 United States
805 447 1000
805 447 1010
Top Executives
Robert A. Bradway 58 2007 Chairman, CEO & President
Ronald D. Sugar 73 2010 Independent Director
Tyler E. Jacks 61 2012 Independent Director
Amy E. Miles 55 2020 Independent Director
Ellen J. Kullman 66 2016 Independent Director
Brian J. Druker 66 2018 Independent Director
Wanda M. Austin 68 2017 Independent Director
R. Sanders Williams 73 2014 Independent Director
Greg C. Garland 65 2013 Independent Director
S. Omar Ishrak 66 2021 Independent Director
Robert A. Eckert 68 2012 Lead Independent Director
Judy L. Gawlik Brown 53 2017 Senior VP & Chair of the Amgen Foundation
Michael V. Drake 0 2022 Independent Director
Charles M. Holley 65 2017 Independent Director
Clear All
Please try another search

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.